EGFR and cancer: Our analyses identified the high correlations between the downregulation of BICD1 and the decreased levels of a couple of markers representing several important pathways associated with cancer progression, including immune checkpoint (PD-L1 related), HGF-MET, JAK2-STAT3-SOCS3, GSK3B, MTOR-S6K, HIF1A, IDH1, and EGFR pathways.